Showing results (291-300 of 773) with videos related to
Sort By:
Pageof 78
JAMA Dermatology|December 24, 2014
Central obesity and high blood pressure in pediatric patients with atopic dermatitisJonathan I Silverberg, Lauren Becker, Mary Kwasny, et al.Journal of the American Academy of Dermatology|March 15, 2003
Mammographic findings in pseudoxanthoma elasticumLionel Bercovitch, Barbara Schepps, Susan Koelliker, et al.The Journal of Clinical and Aesthetic Dermatology|March 21, 2022
Tepilamide Fumarate (PPC-06) Extended Release Tablets in Patients with Moderate-to-Severe Plaque Psoriasis: Safety and Efficacy Results from the Randomized, Double-blind, Placebo-controlled AFFIRM StudyUlrich Mrowietz, Leon Kircik, Kristian Reich, et al.Cutis|February 12, 2015
Reduced degree of irritation during a second cycle of ingenol mebutate gel 0.015% for the treatment of actinic keratosisShelbi C Jim On, Madelaine Haddican, Alex Yaroshinsky, et al.Cutis|April 7, 2015
Disease burden and quality of life in psoriasis patients with and without comorbid psoriatic arthritis: results from National Psoriasis Foundation panel surveysEmily Edson-Heredia, Baojin Zhu, Jiaying Guo, et al.Kidney Medicine|March 30, 2026
Three People With Recurrent Nephrolithiasis and Heterozygous ABCC6 MutationsDouglas Farrell, Jaime Uribarri, Tessa R Pitman, et al.Journal of the American Academy of Dermatology|June 16, 2014
An investigator-initiated, double-blind, vehicle-controlled pilot study: assessment for tachyphylaxis to topically occluded halobetasol 0.05% ointment in the treatment of psoriasisTali Czarnowicki, Rita V Linkner, Mayte Suárez-Fariñas, et al.International Journal of Dermatology|October 17, 2024
Psoriasis management tree based on comorbidityShivkar Amara, Anusha Pasumarthi, Neil Parikh, et al.Journal of the American Academy of Dermatology|January 17, 2012
Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to knowBruce E Strober, Katherine Armour, Ricardo Romiti, et al.Archives of Dermatology|January 19, 2005
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasisAlan Menter, Kenneth Gordon, Wayne Carey, et al.Pageof 78